Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.59 |
| ▸ | TOP2A | P11388 | 2/20 | 0.56 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 5/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TNKS | O95271 | 4/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | GUSB | P08236 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936991 | 0.86 | TOP2A (0.58) | QTRT1TOP2ATOP2BBRD4PARP1 | |
| SCHEMBL29965486 | 0.86 | TOP2A (0.58) | QTRT1TOP2ATOP2BBRD4PARP1 | |
| SCHEMBL28060714 | 0.83 | BRD4 (0.59) | QTRT1TOP2ATOP2BBRD4PARP1 | |
| SCHEMBL6157123 | 0.82 | MAPT (0.56) | QTRT1TOP2ATOP2BBRD4PARP1 | |
| SCHEMBL11576628 | 0.82 | MAPT (0.58) | QTRT1TOP2ATOP2BBRD4MAPT | |
| SCHEMBL27334538 | 0.81 | BRD4 (0.74) | QTRT1TOP2ATOP2BBRD4PARP1 | |
| SCHEMBL8187460 | 0.81 | TOP2A (0.59) | QTRT1TOP2ATOP2BBRD4PARP1 | |
| SCHEMBL942595 | 0.79 | MAPT (0.56) | QTRT1TOP2ATOP2BBRD4PARP1 | |
| SCHEMBL11499700 | 0.79 | TOP2A (0.52) | QTRT1TOP2ATOP2BBRD4PARP1 | |
| SCHEMBL11548431 | 0.79 | TOP2A (0.46) | QTRT1TOP2ATOP2BBRD4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170843-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Pfizer Inc. (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2008149191-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2008-12-11 | — | — | WO | claimed |
| CN-110483418-B | 3-substituted quinazolinone-2-formamide derivative and preparation method and application thereof | 广西师范大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-106008373-B | Disubstituted bicyclic derivative and its application as efflux pump inhibitor in antibacterial | 山东大学 | 2019-02-22 | — | — | CN | disclosed |
| CN-106008373-A | Disubstituted bicyclic derivative and application thereof as efflux pump inhibitor to anti-microbial | 山东大学 | 2016-10-12 | — | — | CN | disclosed |
| US-8530652-B2 | Pyrrolopyrazoles, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530652-B2 | Pyrrolopyrazoles, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8067591-B2 | Pyrrolopyrazole, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067591-B2 | Pyrrolopyrazole, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-1838718-B1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-1838718-B1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110009435-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | disclosed |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | disclosed |
| EP-1838718-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006072831-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2004039843-A1 | IMMUNOGLOBULIN G BINDING POCKET | AMERSHAM BIOSCIENCES AB (SE) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004039765-A1 | USE OF UREA VARIANTS AS AFFINITY LIGANDS | AMERSHAM BIOSCIENCES AB (SE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009435-A1 | HETERO BICYCLIC CARBOXAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CNR2, CYP2C9, CYP2C8 | QTRT1 274/4885TOP2A 3326/4885TOP2B 3059/4885 |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | QTRT1 1738/4885TOP2A 2870/4885TOP2B 2623/4885 |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | QTRT1 1511/4885TOP2A 3072/4885TOP2B 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.